Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data

Briggs, Katharine; Bosc, Nicolas; Camara, Tima; Diaz, Carlos; Drew, Phil; Drewe, William C.; Kors, Jan A.; Mulligen, Erik van; Pastor Maeso, Manuel; Pognan, François; Quintana, Jordi; Sarntivijai, Sirarat; Steger-Hartmann, Thomas

doi:http://dx.doi.org/10.14573/altex.2011181

Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data

License

Citation

Briggs K, Bosc N, Camara T, Diaz C, Drew P, Drewe WC, Kors J, Van Mulligen E, Pastor M, Pognan F, Quintana JR, Sarntivijai S, Steger-Hartmann T. Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data. ALTEX. 2021 Feb 25. DOI: 10.14573/altex.2011181

Abstract

Pre-competitive data sharing can offer the pharmaceutical industry significant benefits in terms of reducing the time and costs involved in getting a new drug to market through more informed testing strategies and knowledge gained by pooling data. If sufficient data is shared and can be co-analyzed, then it can also offer the potential for reduced animal usage and improvements in the in silico prediction of toxicological effects. Data sharing benefits can be further enhanced by applying the FAIR Guiding Principles, reducing time spent curating, transforming and aggregating datasets and allowing more time for data mining and analysis. We hope to facilitate data sharing by other organizations and initiatives by describing lessons learned as part of the Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management (eTRANSAFE) project, an Innovative Medicines Initiative (IMI) partnership which aims to integrate publicly available data sources with proprietary preclinical and clinical data donated by pharmaceutical organizations. Methods to foster trust and overcome non-technical barriers to data sharing such as legal and IPR (intellectual property rights) are described, including the security requirements that pharmaceutical organizations generally expect to be met. We share the consensus achieved among pharmaceutical partners on decision criteria to be included in internal clearance procedures used to decide if data can be shared. We also report on the consensus achieved on specific data fields to be excluded from sharing for sensitive preclinical safety and pharmacology data that could otherwise not be shared.